semaglutide lowers risk of heart issues regardless of weight loss New Science Suggests Improves CV Outcomes Beyond Semaglutide Demonstrates Impressive Heart Benefits
Description
A phase 3 trial found the once-daily pill orforglipron lowered blood sugar and body weight more than oral semaglutide in adults with type 2 diabetes.
Recently, multiple case reports and studies indicating safety risks for these medications and their use in patients planning to undergo general anesthesia have been published, as retained gastric contents can lead to intraoperative aspiration
99% purity verified by HPLC with batch-level COAs available
Would you like to request an appointment
Hydrate faster
INVOKANA (canagliflozin) Official HCP Website
